Drugs.com - Clinical Trials

Vividion Therapeutics Doses First Patient in Phase I Study of RAS-PI3Kα Inhibitor VVD-159642 for Treatment of Advanced Solid Tumors

Vividion Therapeutics Doses First Patient in Phase I St...

May 12, 2025 0

San Diego, CA, USA, Berlin, Germany, April 3, 2025 – Vividion Therapeutics, Inc....

Icotrokinra Results Show 75% of Adolescents with Plaque...

May 12, 2025 0

SPRING HOUSE, Pa. (April 10, 2025) – Johnson & Johnson (NYSE: JNJ) today announc...

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

Allogene Granted Three U.S. FDA Fast Track Designations...

May 12, 2025 0

SOUTH SAN FRANCISCO, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- Allogene Therape...

Theravance Biopharma Presents Two New Ampreloxetine Analyses

Theravance Biopharma Presents Two New Ampreloxetine Ana...

May 12, 2025 0

DUBLIN, April 7, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Bi...

Cellenkos Announces US FDA Orphan Drug Designation Granted to CK0801 (Allogeneic Cord Blood derived T regulatory Cell Product) for Treatment of Aplastic Anemia

Cellenkos Announces US FDA Orphan Drug Designation Gran...

May 12, 2025 0

HOUSTON, April 14, 2025 /PRNewswire/ -- Cellenkos Inc., a clinical-stage biotech...

Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

Verve Therapeutics Receives U.S. FDA Fast Track Designa...

May 12, 2025 0

BOSTON, April 11, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage ...

FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs

FDA Announces Plan to Phase Out Animal Testing Requirem...

May 12, 2025 0

April 10, 2025 -- Today, the U.S. Food and Drug Administration is taking a groun...

Tolebrutinib Phase 3 Data Published in NEJM Demonstrate Benefit on Disability Progression in Multiple Sclerosis

Tolebrutinib Phase 3 Data Published in NEJM Demonstrate...

May 12, 2025 0

Paris, April 8, 2025. The New England Journal of Medicine (NEJM) published posit...

Pfizer Discontinues Development of Oral GLP-1 Receptor Agonist Danuglipron

Pfizer Discontinues Development of Oral GLP-1 Receptor ...

May 12, 2025 0

NEW YORK--(BUSINESS WIRE) April 14, 2025 -- Pfizer Inc. (NYSE: PFE) today announ...

Novo Nordisk Warns Consumers About Counterfeit Ozempic (semaglutide) Injection 1 mg in the US

Novo Nordisk Warns Consumers About Counterfeit Ozempic ...

May 12, 2025 0

PLAINSBORO, N.J., April 14, 2025 /PRNewswire/ -- Novo Nordisk has become aware o...

Click Therapeutics Announces FDA Marketing Authorization for CT-132, the First Prescription Digital Therapeutic for the Preventive Treatment of Episodic Migraine in the United States

Click Therapeutics Announces FDA Marketing Authorizatio...

May 12, 2025 0

NEW YORK, N.Y. (April 15, 2025) – Click Therapeutics, Inc., (“Click”) a leader i...

Bristol Myers Squibb Provides Update on Camzyos Phase 3 ODYSSEY-HCM Trial

Bristol Myers Squibb Provides Update on Camzyos Phase 3...

May 12, 2025 0

PRINCETON, N.J.-- April 14, 2025 (BUSINESS WIRE) -- Bristol Myers Squibb (NYSE:...

Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide

Ironwood Pharmaceuticals Provides Clinical and Regulato...

May 12, 2025 0

BOSTON--(BUSINESS WIRE) April 14, 2025 -- Ironwood Pharmaceuticals, Inc. (Nasda...

BlueRock Therapeutics Announces Publication in Nature of 18-Month Data from Phase 1 Clinical Trial for Bemdaneprocel, an Investigational Cell Therapy for Parkinson’s Disease

BlueRock Therapeutics Announces Publication in Nature o...

May 12, 2025 0

Cambridge MA, USA, April 16, 2025 – BlueRock Therapeutics LP, a clinical-stage c...

Repurposing Blood Pressure Drug Reserpine May Prevent Vision Loss in Inherited Blinding Diseases

Repurposing Blood Pressure Drug Reserpine May Prevent V...

May 12, 2025 0

Tuesday, April 15, 2025 -- New studies in rats suggest the drug reserpine, appro...

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B

Precision BioSciences Receives U.S. FDA Fast Track Desi...

May 12, 2025 0

DURHAM, N.C.--(BUSINESS WIRE)--Apr. 15, 2025-- Precision BioSciences, Inc. (Nasd...

NIH Study Reveals How Inflammation Makes Touch Painful

NIH Study Reveals How Inflammation Makes Touch Painful

May 12, 2025 0

April 23, 2025 -- Researchers at the National Institutes of Health (NIH) have di...

Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia

Bristol Myers Squibb Announces Topline Results from Pha...

May 12, 2025 0

PRINCETON, N.J.--(BUSINESS WIRE) Apr 22, 2025 -- Bristol Myers Squibb (NYSE: BM...

Orforglipron Demonstrated Statistically Significant Eff...

May 12, 2025 0

INDIANAPOLIS, April 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) t...

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission

Aldeyra Therapeutics Achieves Primary Endpoint in Phase...

May 12, 2025 0

LEXINGTON, Mass.--(BUSINESS WIRE)--May 5, 2025-- Aldeyra Therapeutics, Inc. (Nas...

GLISTEN Phase III Trial Results Show Linerixibat Significantly Improves Cholestatic Pruritus in Primary Biliary Cholangitis

GLISTEN Phase III Trial Results Show Linerixibat Signif...

May 12, 2025 0

London, UK 08 May 2025 -- GSK plc (LSE/NYSE: GSK) today announced positive resul...

Boehringer Ingelheim Starts Phase II Study of BI 1584862, Potential First-in-Class Oral Compound as a Treatment for Geographic Atrophy

Boehringer Ingelheim Starts Phase II Study of BI 158486...

May 12, 2025 0

Ingelheim, Germany, May 6, 2025 -- Boehringer Ingelheim today announces the star...

Zepbound (tirzepatide) Showed Superior Weight Loss Over Wegovy (semaglutide) in Complete SURMOUNT-5 Results Published in The New England Journal of Medicine

Zepbound (tirzepatide) Showed Superior Weight Loss Over...

May 12, 2025 0

INDIANAPOLIS, May 11, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) tod...

Icotrokinra Results Show Significant Skin Clearance in Patients with Difficult-to-Treat Scalp and Genital Psoriasis

Icotrokinra Results Show Significant Skin Clearance in ...

May 12, 2025 0

SPRING HOUSE, Pa. (May 9, 2025) – Johnson & Johnson (NYSE: JNJ) today announced ...

1
2
3

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.